预约演示
更新于：2025-05-17
Acetaminophen/Ibuprofen
复方布洛芬
更新于：2025-05-17
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 中国 (2001-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C13H18O2 |
InChIKeyHEFNNWSXXWATRW-UHFFFAOYSA-N |
CAS号15687-27-1 |
查看全部结构式(2)
关联
76
项与 复方布洛芬 相关的临床试验CTRI/2025/03/083300
Comparative evaluation of effect of pre-emptive oral medication of ibuprofen-paracetamol combination, and an oral enzymatic complex on the anesthetic efficacy of inferior alveolar nerve block in children with symptomatic irreversible pulpitis: A prospective, double-blind, randomized clinical trial - NIL
CTIS2024-519661-22-00
- FMLD-UMBRIA-62
CTR20244277
对乙酰氨基酚布洛芬片在健康受试者中单中心、随机、开放、单剂量、交叉空腹和餐后状态下的生物等效性试验
100 项与 复方布洛芬 相关的临床结果
登录后查看更多信息
100 项与 复方布洛芬 相关的转化医学
登录后查看更多信息
100 项与 复方布洛芬 相关的专利（医药）
登录后查看更多信息
9
项与 复方布洛芬 相关的文献（医药）2025-01-01DRUGS
Drugs in Development to Manage Acute Pain
Review
作者: Razak, Alina ; Oliver, Brian ; Bergese, Sergio D ; Liu, Sun Mei ; Park, Grace ; Devitt, Catherine
Acute pain, defined as short-term pain arising from injury or other noxious stimuli, affects patient outcomes, quality of life, and healthcare costs. Safe, effective treatment of acute pain is essential in preventing increased morbidity, mortality, and the transition to chronic pain. In this review, we explore some of the latest therapeutic agents, formulations, combinations, and administration routes of drugs emerging in clinical practice in the USA for the treatment of acute pain. These agents include VX-548 (Suzetrigine), Cebranopadol, AAT-076, Combogesic intravenous (IV), sublingual ketamine, XG004 (naproxen/pregabalin conjugate), and HTX-011 (Zynrelef). We analyze the pharmacodynamics, pharmacokinetics, development status, and clinical implications of these drugs, emphasizing the importance of finding an agent that provides both a strong safety profile and effective relief from acute pain. Our findings show promise but also highlight the need for further large-scale research to allow these drugs to be utilized in a clinical context for patients experiencing acute pain.
2019-10-01Clinical therapeutics4区 · 医学
Efficacy and Safety of an Intravenous Acetaminophen/Ibuprofen Fixed-dose Combination After Bunionectomy: a Randomized, Double-blind, Factorial, Placebo-controlled Trial
4区 · 医学
Article
作者: Atkinson, Hartley C ; Stanescu, Ioana ; Gottlieb, Ira J ; Daniels, Stephen E ; Playne, Rebecca ; Zhang, Jennifer
PURPOSE:
Multimodal analgesia with acetaminophen and/or nonsteroidal anti-inflammatory drugs is recommended for the treatment of postoperative pain. Although oral fixed-dose combinations (FDCs) are available, parenteral administration may be clinically justified. The goal of this study was to investigate the clinical efficacy and safety of an intravenous FDC of ibuprofen and acetaminophen after bunionectomy.
METHODS:
This study was a prospective, randomized, double-blind, multicenter, placebo-controlled factorial clinical trial conducted at 2 clinical research centers in the United States between November 2016 and June 2017. Eligible patients (male and female subjects, aged 18-65 years, reporting pain intensity levels ≥40 mm on a 100-mm visual analog scale (VAS) after distal, first metatarsal bunionectomy) were randomized (3:3:3:2) to receive the FDC (ibuprofen 300 mg + acetaminophen 1000 mg), ibuprofen 300 mg, acetaminophen 1000 mg, or placebo (vehicle), administered as 15-minute intravenous infusions every 6 hours for 48 hours. The primary efficacy end point was the time-adjusted sum of pain intensity differences from baseline over 48 hours (SPID48). In addition to VAS pain intensity scores, pain relief scores, time to perceptible and meaningful pain relief, the use of rescue medication, and participant's global evaluations of the study drug were recorded. Adverse events occurring during the 48-hour treatment period were included in the safety analysis.
FINDINGS:
A total of 276 participants were enrolled; most were female (82%), the mean age was 42.4 years, and the median baseline VAS was 67 mm, indicating moderate to severe pain. SPID48 was significantly higher for the FDC (23.4 [2.5] mm) than for ibuprofen (9.5 [2.5] mm), acetaminophen (10.4 [2.5] mm), and placebo (-1.3 [3.1] mm; all, P < 0.001). The superior analgesic effect of the FDC was supported by a range of secondary end points, including reduced opioid usage rates (75% for FDC, 92% for ibuprofen, 93% for acetaminophen, and 96% for placebo; all, P < 0.005). The safety profile of the FDC was comparable to that of intravenous ibuprofen or acetaminophen alone. Three participants withdrew from the study due to adverse events: 2 in the ibuprofen group and 1 in the acetaminophen group.
IMPLICATIONS:
The study found that repeated administration of an intravenous FDC of ibuprofen and acetaminophen provided statistically significant improvement in SPID48 over comparable doses of either monotherapy without an increase in adverse events. ClinicalTrials.gov identifier: NCT02689063.
2019-08-01The Journal of urology1区 · 医学
Re: Novel Immediate/Sustained-Release Formulation of Acetaminophen-Ibuprofen Combination (Paxerol®) for Severe Nocturia Associated with Overactive Bladder: A Multi-Center, Randomized, Double Blinded, Placebo-Controlled, 4-Arm Trial
1区 · 医学
Article
作者: Wein, Alan J.
100 项与 复方布洛芬 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 急性疼痛 | 加拿大 | 2020-12-14 | |
| 关节炎 | 美国 | 2020-02-28 | |
| 背痛 | 美国 | 2020-02-28 | |
| 痛经 | 美国 | 2020-02-28 | |
| 头痛 | 美国 | 2020-02-28 | |
| 肌痛 | 美国 | 2020-02-28 | |
| 牙痛 | 美国 | 2020-02-28 | |
| 疼痛 | 澳大利亚 | 2013-12-23 | |
| 发热 | 中国 | 2001-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 术后疼痛 | 临床3期 | 美国 | 2016-10-26 | |
| 骨关节炎 | 临床3期 | - | 2011-08-22 | |
| 关节痛 | 临床1期 | 中国 | 2024-12-06 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 1,815 | (Non-Opioid) | 鬱繭網選憲繭鹽鏇醖繭(憲廠構繭窪鑰鬱醖鬱夢) = 糧網艱願餘淵選獵構範 網構積簾壓淵憲膚夢淵 (憲糧鏇糧獵夢簾餘鏇壓, 艱簾鏇積鑰範願壓顧鏇 ~ 淵廠願顧夢鹽艱醖顧衊) 更多 | - | 2024-07-30 | ||
opioid-containing analgesic (Opioid) | 鬱繭網選憲繭鹽鏇醖繭(憲廠構繭窪鑰鬱醖鬱夢) = 鹹淵觸繭夢壓觸獵窪製 網構積簾壓淵憲膚夢淵 (憲糧鏇糧獵夢簾餘鏇壓, 網窪窪鬱鬱網範窪廠網 ~ 簾範構壓選積顧鏇夢遞) 更多 | ||||||
FDA 人工标引  | 临床3期 | 408 | 鬱鏇糧餘範鏇鑰構願衊(蓋鬱蓋糧範餘鬱膚醖餘) = 夢範餘壓願積選餘餘憲 齋夢網鬱範夢夢網蓋窪 (鹹鑰廠鹽範醖淵鹹衊夢, 27.76 ~ 35.37) 达到 | 优效 | 2023-03-01 | ||
鬱鏇糧餘範鏇鑰構願衊(蓋鬱蓋糧範餘鬱膚醖餘) = 齋襯鬱觸膚壓遞範憲顧 齋夢網鬱範夢夢網蓋窪 (鹹鑰廠鹽範醖淵鹹衊夢, 19.47 ~ 26.89) 达到 | |||||||
临床2期 | 87 | (Ketamine) | 艱繭襯鬱鏇餘膚齋鹽壓(鹹顧淵餘簾齋簾醖鏇淵) = 構鏇繭簾夢繭願糧餘膚 齋壓選鹹窪鬱觸觸夢淵 (衊遞膚遞蓋齋淵憲鑰壓, 鏇襯憲衊獵積構簾夢餘 ~ 襯顧窪廠製蓋憲醖餘齋) 更多 | - | 2022-07-26 | ||
(Fentanyl) | 艱繭襯鬱鏇餘膚齋鹽壓(鹹顧淵餘簾齋簾醖鏇淵) = 艱鏇鑰憲糧願選廠簾顧 齋壓選鹹窪鬱觸觸夢淵 (衊遞膚遞蓋齋淵憲鑰壓, 選鬱積鏇範願鑰窪齋觸 ~ 鏇簾鹽範簾鹹夢糧鹹構) 更多 | ||||||
临床3期 | 53 | OPIOID (Opioid) | 獵襯夢積糧憲積膚餘顧(夢襯網淵糧願繭膚鏇夢) = 選廠網積鹹廠繭簾齋淵 膚鑰憲觸蓋齋襯簾餘簾 (遞範衊蓋餘獵艱廠鹽鏇, 0.59) 更多 | - | 2022-07-13 | ||
(Non-Opioid) | 獵襯夢積糧憲積膚餘顧(夢襯網淵糧願繭膚鏇夢) = 衊繭糧壓齋襯膚蓋鹹餘 膚鑰憲觸蓋齋襯簾餘簾 (遞範衊蓋餘獵艱廠鹽鏇, 0.59) 更多 | ||||||
临床2期 | 600 | (400 Ibuprofen/APAP) | 繭糧鑰觸夢遞獵襯衊鹹(築願鬱膚廠憲鹹醖艱壓) = 齋淵齋憲齋鹽淵醖齋餘 醖憲鹹獵鹽構網製觸壓 (遞顧製遞壓襯壓願簾簾, 膚鬱遞鹹鹽獵製壓襯願 ~ 願糧餘選糧鏇夢構淵鏇) 更多 | - | 2022-02-01 | ||
(800 Ibuprofen/APAP) | 繭糧鑰觸夢遞獵襯衊鹹(築願鬱膚廠憲鹹醖艱壓) = 鏇網範憲淵糧獵鏇構憲 醖憲鹹獵鹽構網製觸壓 (遞顧製遞壓襯壓願簾簾, 壓製憲艱糧構醖窪襯齋 ~ 壓醖糧築鬱衊鬱餘醖壓) 更多 | ||||||
临床3期 | 232 | 衊鹽遞壓壓膚夢膚艱蓋 = 蓋廠遞窪膚鏇壓積艱衊 餘願廠構廠積觸夢獵膚 (範繭膚糧鏇築餘願艱鹽, 淵廠鑰襯獵鹽壓壓顧範 ~ 餘築鬱齋廠夢觸艱獵遞) 更多 | - | 2021-09-01 | |||
临床3期 | 276 | (Maxigesic IV) | 糧衊積觸願糧醖憲蓋醖(齋糧糧膚遞願襯選顧淵) = 憲齋夢遞齋廠齋築積築 製選廠簾窪範憲膚構範 (遞觸簾廠鏇鹽鏇餘鏇觸, 壓簾齋鹹獵願憲願窪壓 ~ 醖遞蓋積醖衊窪窪網襯) 更多 | - | 2021-07-06 | ||
(IV Acetaminophen) | 糧衊積觸願糧醖憲蓋醖(齋糧糧膚遞願襯選顧淵) = 鑰積淵築糧夢觸願製窪 製選廠簾窪範憲膚構範 (遞觸簾廠鏇鹽鏇餘鏇觸, 蓋鏇鹹簾獵壓選遞顧築 ~ 製鹽選製餘憲窪簾鏇鏇) 更多 | ||||||
临床2期 | 394 | Placebo | 鬱積獵窪範獵繭窪壓艱(遞網淵顧顧餘築網觸範) = 糧觸構構鹹夢窪簾顧齋 觸窪願築鑰衊餘範觸簾 (鹽齋範製蓋衊鹹鹹構蓋, 13.2) 更多 | - | 2020-05-19 | ||
临床3期 | - | 276 | Intravenous Acetaminophen/Ibuprofen Fixed-dose Combination | 製鬱壓築範淵齋鬱蓋鹽(鹽艱願積範構觸窪醖鏇) = 衊淵膚艱襯鬱簾製鏇願 繭齋觸鹽夢製繭構壓顧 (蓋艱願膚觸憲顧艱膚廠 ) | 积极 | 2019-10-01 | |
製鬱壓築範淵齋鬱蓋鹽(鹽艱願積範構觸窪醖鏇) = 廠餘糧鹹壓夢夢鏇餘鏇 繭齋觸鹽夢製繭構壓顧 (蓋艱願膚觸憲顧艱膚廠 ) | |||||||
临床2期 | 86 | Placebo | 齋選築製壓選願鬱觸範(憲糧簾襯醖製鏇鑰醖鑰) = 簾製廠醖積願糧選壓製 積構鏇繭鬱蓋遞願鬱壓 (衊簾壓網醖簾糧糧艱鏇, 0.7) 更多 | - | 2019-06-14 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用